Tocilizumab [roactemra] (DrugBank: Tocilizumab)
18 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
40 | Takayasu arteritis | 0 |
41 | Giant cell arteritis | 0 |
42 | Polyarteritis nodosa | 0 |
43 | Microscopic polyangiitis | 0 |
46 | Malignant rheumatoid arthritis | 1 |
50 | Dermatomyositis | 0 |
51 | Scleroderma | 0 |
53 | Sjogren syndrome | 0 |
54 | Adult still disease | 0 |
55 | Relapsing polychondritis | 0 |
56 | Behcet disease | 0 |
86 | Pulmonary arterial hypertension | 0 |
107 | Juvenile idiopathic arthritis [Systemic juvenile idiopathic arthritis (~Mar 2018)] | 0 |
266 | Familial mediterranean fever | 0 |
271 | Ankylosing spondylitis | 0 |
331 | Idiopathic multicentric castleman disease | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01254331 (ClinicalTrials.gov) | February 2011 | 3/12/2010 | An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment | Open Label, Multicenter, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Monotherapy or in Combination With MTX in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non Biologic DMARDs | Rheumatoid Arthritis | Drug: tocilizumab [RoActemra] | Hoffmann-La Roche | NULL | Completed | 18 Years | N/A | All | 51 | Phase 3 | Tunisia |